CNST Constellation Pharmaceuticals, Inc. Stock Quote

CNST [NASD]

Index	-	P/E	-	EPS (ttm)	-2.29	Insider Own	0.75%	Shs Outstand	47.54M	Perf Week	10.69%
Market Cap	1.72B	Forward P/E	-	EPS next Y	-3.33	Insider Trans	-6.90%	Shs Float	47.22M	Perf Month	3.34%
Income	-113.20M	PEG	-	EPS next Q	-0.76	Inst Own	-	Short Float	11.23%	Perf Quarter	49.73%
Sales	-	P/S	-	EPS this Y	11.70%	Inst Trans	0.10%	Short Ratio	7.62	Perf Half Y	27.35%
Book/sh	9.31	P/B	3.83	EPS next Y	-19.80%	ROA	-25.00%	Target Price	45.67	Perf Year	-2.70%
Cash/sh	10.16	P/C	3.51	EPS next 5Y	-	ROE	-28.90%	52W Range	17.00 - 50.90	Perf YTD	23.68%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-29.92%	Beta	-
Dividend %	-	Quick Ratio	15.80	Sales past 5Y	-	Gross Margin	-	52W Low	109.82%	ATR	2.30
Employees	106	Current Ratio	15.80	Sales Q/Q	-	Oper. Margin	-	RSI (14)	64.74	Volatility	9.37% 7.08%
Optionable	Yes	Debt/Eq	0.07	EPS Q/Q	13.20%	Profit Margin	-	Rel Volume	0.19	Prev Close	35.62
Shortable	Yes	LT Debt/Eq	0.05	Earnings	Oct 29 BMO	Payout	-	Avg Volume	696.08K	Price	35.67
Recom	2.10	SMA20	15.27%	SMA50	24.89%	SMA200	24.63%	Volume	16,986	Change	0.14%

Jan-25-21

Upgrade

BMO Capital Markets

Market Perform → Outperform

$50

Sep-08-20

Downgrade

Oppenheimer

Outperform → Perform

Jul-20-20

Resumed

Jefferies

Buy

Jun-24-20

Initiated

JMP Securities

Mkt Perform

$36

May-07-20

Reiterated

H.C. Wainwright

Buy

$50 → $75

Feb-13-20

Initiated

SunTrust

Buy

$50

Feb-07-20

Initiated

Cowen

Outperform

Jan-09-20

Downgrade

BMO Capital Markets

Outperform → Market Perform

$43 → $42

Sep-04-19

Initiated

RBC Capital Mkts

Outperform

$20

Jan-29-19

Initiated

Robert W. Baird

Outperform

$17

Dec-20-18

Initiated

H.C. Wainwright

Buy

$18

Dec-20-18

Initiated

H.C. Wainwright

Buy

Aug-13-18

Initiated

JP Morgan

Overweight

$17

Jan-25-21 12:32PM	Pharma Stock Ideas: Why BMO Is Recommending Regeneron, Constellation Benzinga
Jan-07-21 09:30AM	Constellation Pharmaceuticals Appoints Brendan Delaney as Chief Commercial Officer GlobeNewswire +5.26%
Jan-06-21 10:00AM	Constellation Pharmaceuticals to Present at J.P. Morgan Healthcare Conference GlobeNewswire
Dec-07-20 04:20PM	Here Are The Winners Of This Year's Biggest Blood Cancer Meeting Investor's Business Daily +34.10%
Dec-06-20 08:00AM	Constellation Pharmaceuticals Provides Update of MANIFEST Study for CPI-0610 at ASH Meeting GlobeNewswire
Nov-23-20 01:00PM	Constellation Pharmaceuticals to Host Analyst / Investor Event to Discuss Update of MANIFEST Clinical Trial for CPI-0610 Presented at ASH Meeting GlobeNewswire
Nov-10-20 10:22AM	Was The Smart Money Wrong About Constellation Pharmaceuticals, Inc. (CNST)? Insider Monkey
Oct-29-20 07:00AM	Constellation Pharmaceuticals Announces Third-Quarter 2020 Financial Results GlobeNewswire -19.94%
06:00AM	Constellation Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Oct-19-20 02:00PM	Constellation Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2020 Results GlobeNewswire
Sep-10-20 10:06AM	Hedge Funds Are Betting On Constellation Pharmaceuticals, Inc. (CNST) Insider Monkey
Sep-09-20 03:00PM	Constellation Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences GlobeNewswire
Sep-03-20 10:21AM	Benzinga's Top Upgrades, Downgrades For September 3, 2020 Benzinga
Aug-05-20 07:00AM	Constellation Pharmaceuticals Announces Second-Quarter 2020 Financial Results, Provides Regulatory Update GlobeNewswire -7.39%
Aug-04-20 11:08AM	Why Constellation Pharmaceuticals (CNST) Might Surprise This Earnings Season? Zacks
Jul-31-20 12:00PM	Constellation Pharmaceuticals to Host Conference Call to Discuss Second Quarter 2020 Results GlobeNewswire
Jul-20-20 12:15PM	Did Hedge Funds Make The Right Call On Constellation Pharmaceuticals, Inc. (CNST) ? Insider Monkey
Jul-15-20 01:15PM	Steven Cohen Homes in on Otonomy GuruFocus.com
Jul-06-20 12:13PM	What Type Of Shareholders Make Up Constellation Pharmaceuticals, Inc.'s (NASDAQ:CNST) Share Registry? Simply Wall St.
Jun-22-20 04:35PM	Repare and Forma Shares Gobbled Up in IPO GuruFocus.com +6.57%
Jun-16-20 08:27PM	Constellation Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire
Jun-15-20 04:01PM	Constellation Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire +9.33%
09:47AM	Is Constellation Pharmaceuticals, Inc. (CNST) A Good Stock To Buy? Insider Monkey
Jun-12-20 02:30AM	Constellation Pharmaceuticals Provides Updates of MANIFEST Study for CPI-0610 and EZH2 Franchise GlobeNewswire
Jun-10-20 11:30AM	Constellation Pharmaceuticals to Participate in Investor Conference GlobeNewswire
Jun-08-20 08:00AM	Constellation Pharmaceuticals Announces Appointment of Dr. Jeffrey Humphrey as Chief Medical Officer GlobeNewswire
May-29-20 09:00AM	Constellation Pharmaceuticals to Participate in Investor Conference GlobeNewswire +5.74%
May-28-20 12:00PM	Constellation Pharmaceuticals to Host Analyst / Investor Event to Discuss Update of MANIFEST Clinical Trial for CPI-0610 GlobeNewswire
May-25-20 12:00PM	Constellation Pharmaceuticals, Inc. (CNST) Upgraded to Buy: What Does It Mean for the Stock? Zacks
May-14-20 09:24AM	Is Constellation (CNST) Stock a Solid Choice Right Now? Zacks -5.37%
08:00AM	Constellation Pharmaceuticals Provides Update of Preliminary Data for CPI-0610 in Three EHA Abstracts GlobeNewswire
May-09-20 08:22PM	Was The Smart Money Right About Constellation Pharmaceuticals (CNST)? Insider Monkey
May-06-20 03:32PM	Constellation Pharmaceuticals (CNST) Q1 2020 Earnings Call Transcript Motley Fool +12.33%
07:00AM	Constellation Pharmaceuticals Announces First-Quarter 2020 Financial Results GlobeNewswire
May-05-20 02:06PM	Constellation Pharmaceuticals to Participate in Two Investor Conferences GlobeNewswire +5.07%
Apr-28-20 09:00AM	Constellation Pharmaceuticals to Host Conference Call to Discuss First Quarter 2020 Results GlobeNewswire
Apr-24-20 12:00PM	What Makes Constellation Pharmaceuticals, Inc. (CNST) a New Buy Stock Zacks +8.52%
Apr-06-20 07:00AM	Constellation Pharmaceuticals Announces Appointment of Dr. Richard Levy to Board of Directors GlobeNewswire
Mar-24-20 08:58AM	Why You Shouldn't Bet Against Constellation Pharmaceuticals (CNST) Stock Zacks +7.32%
Mar-16-20 12:00PM	What Makes Constellation Pharmaceuticals, Inc. (CNST) a New Buy Stock Zacks -19.61%
Mar-10-20 04:12PM	Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2019 Financial Results GlobeNewswire
03:00PM	Constellation Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Mar-06-20 01:00PM	Constellation Pharmaceuticals to Host Conference Call to Discuss Fourth Quarter 2019 Results GlobeNewswire
Feb-26-20 09:00AM	Constellation Pharmaceuticals to Present at Investor Conferences GlobeNewswire -5.20%
Feb-19-20 10:35AM	Revolution Medicines Joins Amgen and Mirati in Quest for New Type of Cancer Drugs GuruFocus.com
Jan-09-20 02:50PM	Top Biotech Stocks for Q1 2020 Investopedia -6.93%
Jan-06-20 12:34PM	Constellation Pharmaceuticals to Present at J.P. Morgan Healthcare Conference GlobeNewswire -8.22%
Dec-27-19 02:19PM	Biotech Rally Sends Nasdaq to 9000: ETFs in Focus Zacks -5.07%
Dec-16-19 06:00AM	Hedge Funds Have Never Been More Bullish On Constellation Pharmaceuticals, Inc. (CNST) Insider Monkey +14.50%
Dec-13-19 04:05PM	Constellation Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares GlobeNewswire
Dec-10-19 09:05PM	Constellation Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire
Dec-09-19 04:18PM	Constellation Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire -17.30%
10:00AM	Constellation Pharmaceuticals Provides Updated Preliminary Data from MANIFEST Clinical Trial with CPI-0610 in Oral and Poster Presentations at ASH GlobeNewswire
Dec-02-19 11:00AM	Constellation Pharmaceuticals to Host Analyst/Investor Meeting at ASH to Discuss Updated Preliminary Data from the MANIFEST Clinical Trial with CPI-0610 GlobeNewswire
Nov-29-19 12:15PM	Biotech Tops in November: Best ETFs & Stocks Zacks +8.99%
Nov-25-19 12:43PM	Top Small Cap Stocks for December 2019 Investopedia
Nov-13-19 09:00AM	Constellation Pharmaceuticals to Participate in Upcoming Investor Conferences GlobeNewswire +5.23%
Nov-07-19 10:34PM	Hedge Funds Have Never Been More Bullish On Constellation Pharmaceuticals, Inc. (CNST) Insider Monkey +13.24%
Nov-06-19 11:35AM	Constellation shares soar 95% after promising data from rare disease trial MarketWatch +90.25%
09:00AM	Constellation Pharmaceuticals Announces Third-Quarter and Nine-Month 2019 Financial Results GlobeNewswire
06:48AM	Constellation Pharma Skyrockets More Than 100% on Promising Drug Trial Data Investing.com
Oct-31-19 10:00AM	Here's Why Momentum Investors Will Love Constellation Pharmaceuticals, Inc. (CNST) Zacks
Oct-14-19 08:06AM	Will Constellation Pharmaceuticals Continue to Surge Higher? Zacks +9.99%
Oct-10-19 07:00AM	Constellation Pharmaceuticals Announces MANIFEST Data Updates Will Be Provided in Oral and Poster Sessions on December 9 at ASH GlobeNewswire
Oct-04-19 08:52AM	Constellation Pharmaceuticals (CNST) Looks Good: Stock Adds 8.3% in Session Zacks
Oct-01-19 07:00AM	Constellation Pharmaceuticals Announces $65 Million Private Placement with New and Existing Investors GlobeNewswire +17.49%
Sep-26-19 12:00PM	Constellation Pharmaceuticals to Present at Cantor Global Healthcare Conference GlobeNewswire
Sep-24-19 07:00AM	Constellation Pharmaceuticals Advances CPI-0209 into Clinical Trials, Expanding its EZH2 Franchise GlobeNewswire
Sep-23-19 07:17PM	Investors May Want to Follow the Progress of These Biotechs GuruFocus.com -5.91%
Aug-21-19 09:00AM	Constellation Pharmaceuticals to Participate in Two Investor Conferences GlobeNewswire
Aug-07-19 04:05PM	Constellation Pharmaceuticals Announces Second-Quarter and Six-Month 2019 Financial Results GlobeNewswire
Jul-25-19 01:39PM	Did You Manage To Avoid Constellation Pharmaceuticals's (NASDAQ:CNST) 16% Share Price Drop? Simply Wall St.
Jun-13-19 02:57PM	Constellation Pharmaceuticals to Present at BMO Prescriptions for Success Healthcare Conference GlobeNewswire
Jun-12-19 09:00AM	Constellation Pharmaceuticals Presentation Highlights Enhanced EZH2 Target Engagement, Leading to Second-Generation EZH2 Inhibitor CPI-0209 GlobeNewswire -5.80%
Jun-03-19 09:00AM	Interim Data for CPI-0610 in MANIFEST Clinical Trial Showed Signals of Clinical Activity in Myelofibrosis Patients GlobeNewswire +7.19%
May-31-19 11:00AM	Constellation Pharmaceuticals to Present at Jefferies Healthcare Conference GlobeNewswire
May-23-19 10:28AM	Constellation Pharmaceuticals to Host Analyst/Investor Meeting at ASCO to Discuss Interim Update of Data of CPI-0610 in MANIFEST Clinical Trial GlobeNewswire
May-20-19 07:00AM	Constellation Pharmaceuticals Presents Poster on Studies of CPI-0209 in Bladder Cancer at AACR Meeting GlobeNewswire -15.15%
May-16-19 09:00AM	Constellation Pharmaceuticals Provides Interim Update of Data for CPI-0610 in ASCO and EHA Abstracts GlobeNewswire
May-08-19 04:15PM	Constellation Pharmaceuticals Announces First-Quarter 2019 Financial Results GlobeNewswire
Apr-19-19 08:00AM	Constellation Pharmaceuticals to Present at the Solebury Trout Class of 2018 Biotech IPOs Investor Day GlobeNewswire
Apr-10-19 07:01PM	Jim Cramer: What Dirty Lemon Tells Us About Market Tops and Millennials TheStreet.com
Mar-14-19 05:24PM	Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2018 Financial Results GlobeNewswire +9.65%
Mar-06-19 02:35PM	Constellation Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire -8.06%
Mar-04-19 07:00AM	Constellation Pharmaceuticals Appoints Jessica Christo as Chief Product Development Officer GlobeNewswire
Feb-25-19 09:02AM	What's in Store for Universal Health (UHS) Q4 Earnings? Zacks +13.14%
Feb-22-19 01:24PM	Constellation Pharmaceuticals to Present at Upcoming Investor Conferences GlobeNewswire -9.51%
Feb-20-19 07:00AM	Constellation Pharmaceuticals Announces Appointment to Board of Directors GlobeNewswire
Feb-12-19 08:52AM	Molina Healthcare (MOH) Q4 Earnings & Revenues Top Estimates Zacks
Feb-08-19 10:05AM	Ensign Group's (ENSG) Q4 Earnings Top Estimates, Surge Y/Y Zacks
10:03AM	MEDNAX (MD) Q4 Earnings Surpass Estimates, Increase Y/Y Zacks
Feb-05-19 09:17AM	Can Higher Revenues Buoy T-Mobile's (TMUS) Q4 Earnings? Zacks +6.83%
Feb-04-19 09:50AM	Will Revenue Growth Support GoPro's (GPRO) Q4 Earnings? Zacks +15.83%
Jan-03-19 07:00AM	Constellation Pharmaceuticals Provides Update on MANIFEST Clinical Trial of CPI-0610 in Myelofibrosis, Reviews 2018 Accomplishments, and Announces 2019 Data Disclosure Plans for Lead Programs GlobeNewswire +5.02%
Dec-20-18 01:34PM	Constellation Pharmaceuticals to Present at J.P. Morgan Healthcare Conference GlobeNewswire -5.31%
Dec-11-18 08:22AM	The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings Benzinga
Dec-10-18 04:49PM	Constellation Pharmaceuticals Initiates Phase 2 Portion of ProSTAR Clinical Trial in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) GlobeNewswire
Nov-29-18 02:00PM	Constellation Pharmaceuticals to Present at BMO Healthcare Conference GlobeNewswire
09:22AM	Constellation Pharmaceuticals Appoints Patrick Trojer, Ph.D., as Chief Scientific Officer GlobeNewswire
Nov-21-18 07:20AM	Factors of Influence in 2018, Key Indicators and Opportunity within Sphere 3D, Solar Senior Capital, The Intergroup, Constellation Pharmaceuticals, Sonoma Pharmaceuticals, and OFS Capital New Research Emphasizes Economic Growth GlobeNewswire

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. Its lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors. The company is also developing CPI-0209 that is in Phase I dose escalation portion of a Phase I/II clinical trial to treat solid tumors. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Valentine Karen	See Remarks	Jan 19	Option Exercise	11.50	17,203	197,835	17,203	Jan 20 05:56 PM
Valentine Karen	See Remarks	Jan 19	Sale	33.97	17,203	584,463	0	Jan 20 05:56 PM
Reeve Emma	Chief Financial Officer	Dec 21	Option Exercise	6.81	5,720	38,975	5,720	Dec 22 04:53 PM
GOLDSMITH MARK A	Director	Dec 21	Sale	35.02	4,020	140,769	139,043	Dec 28 04:02 PM
Reeve Emma	Chief Financial Officer	Dec 21	Sale	35.11	5,720	200,805	0	Dec 22 04:53 PM
Reeve Emma	Chief Financial Officer	Jun 08	Option Exercise	7.60	589	4,476	589	Jun 10 06:50 PM
Reeve Emma	Chief Financial Officer	Jun 08	Sale	37.55	589	22,118	0	Jun 10 06:50 PM
Raythatha Jigar	See Remarks	May 12	Option Exercise	5.51	9,209	50,742	24,170	May 13 06:25 PM
GOLDSMITH MARK A	Director	May 12	Option Exercise	4.12	4,225	17,399	147,288	May 13 06:29 PM
Senderowicz Adrian	Chief Medical Officer	May 12	Option Exercise	5.51	9,357	51,557	25,241	May 13 06:30 PM
Audia James E	Director	May 12	Sale	50.10	6,100	305,622	25,434	May 13 06:30 PM
Senderowicz Adrian	Chief Medical Officer	May 12	Sale	50.18	9,357	469,488	15,884	May 13 06:30 PM
GOLDSMITH MARK A	Director	May 12	Sale	50.05	4,225	211,474	143,063	May 13 06:29 PM
Raythatha Jigar	See Remarks	May 12	Sale	50.17	9,209	461,981	14,961	May 13 06:25 PM
Reeve Emma	Chief Financial Officer	May 11	Option Exercise	8.92	16,062	143,269	16,062	May 12 09:41 PM
Raythatha Jigar	See Remarks	May 11	Option Exercise	5.51	26	143	14,987	May 13 06:25 PM
GOLDSMITH MARK A	Director	May 11	Option Exercise	1.55	100	155	143,163	May 13 06:29 PM
GOLDSMITH MARK A	Director	May 11	Sale	50.00	100	5,000	143,063	May 13 06:29 PM
Raythatha Jigar	See Remarks	May 11	Sale	50.00	26	1,300	14,961	May 13 06:25 PM
Reeve Emma	Chief Financial Officer	May 11	Sale	49.53	16,062	795,623	0	May 12 09:41 PM
Reeve Emma	Chief Financial Officer	May 08	Option Exercise	9.85	12,741	125,467	12,741	May 12 09:41 PM
Reeve Emma	Chief Financial Officer	May 08	Sale	49.53	12,741	631,055	0	May 12 09:41 PM
GOLDSMITH MARK A	Director	May 06	Option Exercise	4.26	11,463	48,825	154,526	May 07 04:25 PM
Valentine Karen	See Remarks	May 06	Option Exercise	10.96	12,566	137,749	12,566	May 07 04:34 PM
Trojer Patrick	Chief Scientific Officer	May 06	Option Exercise	7.04	10,000	70,385	10,000	May 07 04:39 PM
Trojer Patrick	Chief Scientific Officer	May 06	Sale	45.16	10,000	451,553	0	May 07 04:39 PM
Valentine Karen	See Remarks	May 06	Sale	40.10	12,566	503,897	0	May 07 04:34 PM
Audia James E	Director	May 06	Sale	45.15	7,500	338,600	31,534	May 07 04:28 PM
GOLDSMITH MARK A	Director	May 06	Sale	45.06	11,463	516,545	143,063	May 07 04:25 PM
GOLDSMITH MARK A	Director	May 05	Option Exercise	3.50	3,145	11,006	146,208	May 07 04:25 PM
Valentine Karen	See Remarks	May 05	Option Exercise	11.50	4,744	54,556	4,744	May 07 04:34 PM
Valentine Karen	See Remarks	May 05	Sale	40.01	4,744	189,817	0	May 07 04:34 PM
GOLDSMITH MARK A	Director	May 05	Sale	40.01	3,145	125,824	143,063	May 07 04:25 PM
Valentine Karen	See Remarks	Apr 27	Option Exercise	11.50	400	4,600	400	Apr 29 08:03 PM
GOLDSMITH MARK A	Director	Apr 27	Option Exercise	1.55	400	620	143,463	Apr 29 08:20 PM
Valentine Karen	See Remarks	Apr 27	Sale	40.13	400	16,052	0	Apr 29 08:03 PM
GOLDSMITH MARK A	Director	Apr 27	Sale	40.12	400	16,049	143,063	Apr 29 08:20 PM
Valentine Karen	See Remarks	Apr 20	Option Exercise	11.50	789	9,074	789	Apr 22 08:17 PM
Valentine Karen	See Remarks	Apr 20	Sale	33.65	789	26,550	0	Apr 22 08:17 PM
Reeve Emma	Chief Financial Officer	Apr 17	Option Exercise	6.61	760	5,024	760	Apr 20 05:53 PM
Valentine Karen	See Remarks	Apr 17	Option Exercise	11.50	2,300	26,450	2,300	Apr 20 05:52 PM
Valentine Karen	See Remarks	Apr 17	Sale	35.19	2,300	80,939	0	Apr 20 05:52 PM
Reeve Emma	Chief Financial Officer	Apr 17	Sale	35.29	760	26,820	0	Apr 20 05:53 PM
Valentine Karen	See Remarks	Apr 16	Option Exercise	11.50	2,998	34,477	2,998	Apr 20 05:52 PM
Valentine Karen	See Remarks	Apr 16	Sale	33.57	2,998	100,637	0	Apr 20 05:52 PM
Reeve Emma	Chief Financial Officer	Apr 14	Option Exercise	8.76	1,225	10,731	1,225	Apr 16 02:31 PM
Reeve Emma	Chief Financial Officer	Apr 14	Sale	35.20	1,225	43,123	0	Apr 16 02:31 PM
Valentine Karen	See Remarks	Apr 09	Option Exercise	8.76	635	5,563	635	Apr 13 04:56 PM
Reeve Emma	Chief Financial Officer	Apr 09	Option Exercise	7.78	700	5,449	589	Apr 13 04:55 PM
Reeve Emma	Chief Financial Officer	Apr 09	Sale	35.02	700	24,513	0	Apr 13 04:55 PM
Valentine Karen	See Remarks	Apr 09	Sale	35.02	635	22,236	0	Apr 13 04:56 PM
COLUMN GROUP L P	10% Owner	Mar 20	Buy	23.15	5,539	128,228	6,051,376	Mar 23 06:57 PM
COLUMN GROUP L P	10% Owner	Mar 20	Buy	23.15	5,539	128,228	6,051,376	Mar 23 06:59 PM
COLUMN GROUP L P	10% Owner	Mar 19	Buy	22.38	36,135	808,701	6,045,837	Mar 23 06:59 PM
COLUMN GROUP L P	10% Owner	Mar 19	Buy	22.38	36,135	808,701	6,045,837	Mar 23 06:57 PM
Valentine Karen	See Remarks	Mar 09	Option Exercise	8.76	617	5,405	617	Mar 11 04:11 PM
Valentine Karen	See Remarks	Mar 09	Sale	32.03	617	19,763	0	Mar 11 04:11 PM
Reeve Emma	Chief Financial Officer	Feb 13	Option Exercise	8.04	5,521	44,389	5,521	Feb 14 05:09 PM
Valentine Karen	See Remarks	Feb 13	Option Exercise	10.33	4,473	46,217	4,473	Feb 14 05:09 PM
Valentine Karen	See Remarks	Feb 13	Sale	35.07	4,473	156,859	0	Feb 14 05:09 PM
Reeve Emma	Chief Financial Officer	Feb 13	Sale	35.06	5,521	193,539	0	Feb 14 05:09 PM
Valentine Karen	See Remarks	Feb 12	Option Exercise	11.50	1,500	17,250	1,500	Feb 14 05:09 PM
Reeve Emma	Chief Financial Officer	Feb 12	Option Exercise	8.04	1,103	8,868	1,103	Feb 14 05:09 PM
Valentine Karen	See Remarks	Feb 12	Sale	35.02	1,500	52,527	0	Feb 14 05:09 PM
Reeve Emma	Chief Financial Officer	Feb 12	Sale	35.02	1,103	38,624	0	Feb 14 05:09 PM
Reeve Emma	Chief Financial Officer	Feb 11	Option Exercise	7.67	8,642	66,308	7,212	Feb 12 05:36 PM
Valentine Karen	See Remarks	Feb 11	Option Exercise	11.50	8,550	98,325	8,550	Feb 12 05:36 PM
Valentine Karen	See Remarks	Feb 11	Sale	35.03	8,550	299,507	0	Feb 12 05:36 PM
Reeve Emma	Chief Financial Officer	Feb 11	Sale	35.04	8,642	302,816	0	Feb 12 05:36 PM
Reeve Emma	Chief Financial Officer	Feb 10	Option Exercise	7.60	200	1,520	200	Feb 12 05:36 PM
Valentine Karen	See Remarks	Feb 10	Option Exercise	11.50	14,096	162,104	14,096	Feb 12 05:36 PM
Valentine Karen	See Remarks	Feb 10	Sale	33.51	14,096	472,357	0	Feb 12 05:36 PM
Reeve Emma	Chief Financial Officer	Feb 10	Sale	35.00	200	7,000	0	Feb 12 05:36 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience